Abstract Dynamic remodeling of the actin cytoskeleton plays an essential role in cell migration and various signaling processes in living cells. One of the critical factors that controls the nucleation of new actin filaments in eukaryotic cells is the actin-related
Introduction
Actin is the major constituent of the cytoskeleton that participates in various cellular events including motility, endocytosis, cellular shape support and protein and organelle trafficking (Collins et al. 2011; Saarikangas et al. 2010; Peleg et al. 2011) . In recent years, processes and signaling pathways induced by its reorganization have been thoroughly studied and a variety of cytoskeleton-interacting proteins have been revealed.
It has been shown that the actin-related protein 2/3 (Arp2/ 3) complex, in combination with other proteins including the N-WASP/WAVE family of proteins (Chen et al. 2010; Lebensohn and Kirschner 2009; Sarmiento et al. 2008) , cortactin (Weed et al. 2000; Weed and Parsons 2001) and small G-proteins (Watanabe et al. 2010; Sun et al. 2007; Bosse et al. 2007) , is involved in regulation of the actin cytoskeleton nucleation and assembly (Firat-Karalar and Welch 2011; Soderling 2009 ). The Arp2/3 complex is considered to be a key participant in the formation of a stable multimer of actin monomers that helps stabilize the actindimer intermediates and promotes branching of the F-actin filaments (Volkmann et al. 2001) . The complex consists in two actin-related proteins named Arp2 and Arp3 (encoded by the ARP2 and ARP3 genes, respectively), which closely resemble the structure of monomeric actin and five additional subunits ARPC1-5 (Pollard 2007; Rouiller et al. 2008 ). This complex is targeted to the sites of new actin polymerization, binds to the side of the existing filaments and aligns in a similar manner to an actin dimer (Robinson et al. 2001; Volkmann et al. 2001) . Therefore, the Arp2/3 complex nucleates the formation of new filaments that extend from the sides Daria V. Ilatovskaya and Vladislav Chubinskiy-Nadezhdin made equal contributions.
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of existing filaments at a 70°angle to form a dense network of the Y-branched F-actin (Rouiller et al. 2008) .
Since 1994, when the Arp2/3 was first characterized in Acanthamoeba (Machesky et al. 1994) , various cellular processes involving this protein complex have been discovered. It has been shown that inhibition of the Arp2/3 complex results in the control of synaptic plasticity (Nakamura et al. 2011) , contributes to the formation of the filopodia (Spillane et al. 2011) , regulates endosome shape and trafficking (Duleh and Welch 2010) and is engaged in the mechanism of ion channel regulation by cortactin . The Arp2/3 complex is essential for mesenchymal invasion and formation of invadopodia and lamellipodia (Yamaguchi et al. 2005; Sarmiento et al. 2008) . It was reported that invasive cells collected from mouse primary breast tumors in an in vivo invasion assay, show an increased expression of Arp2/3 (Wang et al. 2004 ). Moreover, the Arp 2/3 complex contributes to cancer cell migration and invasion in human cancers, including head and neck squamous cells (Kinoshita et al. 2012) .
Although there have been considerable amounts of data accumulated on the role of the Arp2/3 complex in cytoskeleton dynamics, its participation in cell motility and formation of actin-based protrusions has been underwhelming. Studies have revealed that disrupting the Arp2/3 inhibited lamellipodia formation (Machesky and Insall 1998; Steffen et al. 2006) ; however, other studies have also shown that 90 % knockdown of the Arp2/3 complex subunits in mouse fibroblasts had no effect of the lamellipodia formation (di Nardo et al. 2005) . In 2012, two papers were published on this subject that provided insights into the Arp2/3 complex's critical role in lamellipodia extension and directional migration. Suraneni et al. (2012) showed that ARPC-/-fibroblasts were unable to extend lamellipodia and exhibited a strong defect in persistent directional migration. Similarly, stable fibroblastsderived cell lines depleted of the Arp2/3 complex lacked lamellipodia and showed defective random cell motility that relied on a filopodia-based protrusion system (Wu et al. 2012) . It is clear from these studies that depletion of Arp2/3 affects lamellipodia formation. The current study provides support to the fact that the Arp2/3 complex is involved in cell motility and lamellipodia formation.
The exact mechanism by which the Arp2/3 complex affects the cell has yet to be determined. Various attempts to chemically activate or inhibit the Arp2/3 complex remain of particular interest. Nolen and colleagues identified and characterized novel small molecule inhibitors of the Arp2/3 complex. The authors studied different modifications of potential Arp2/ 3 inhibitors that were initially discovered by screening a library of over 400,000 possible molecules (Nolen et al. 2009 ). CK-0944636 (abbreviated CK-636) binds to different sites on the Arp2/3 complex and inhibits its ability to nucleate actin microfilaments. A compound CK-0944666 (abbreviated CK-666) has a fluorobenzene rather than the thiophen ring of CK-636 and was described to be a better inhibitor of actin polymerization that binds more tightly than the originally identified CK-636. Recently, the crystal structure of CK-666 bound to the Arp2/3 complex has been reported, which revealed that CK-666 binds between the Arp2 and Arp3 subunits to stabilize the inactive conformation of the complex (Baggett et al. 2012; Nolen et al. 2009 ).
CK-666 was recently used to study the contribution of the Arp2/3 complex and actin filaments to mouse oocyte division and cytokinesis (Sun et al. 2011) . Disruption of the Arp2/3 complex by CK-666 caused failure of the oocyte to asymmetrically divide, failure of the spindle to migrate and failure of the oocyte to form properly and undergo cytokinesis. In our recent project, we also utilized CK-666 in studies of ion channels in the epithelial cells. This inhibitor allowed us to identify the Arp2/3 complex's involvement in the regulation of the epithelial Na + channel (ENaC) by cortactin. Importantly, cortactin mutants used in our study, including the mutant W22A that is unable to bind the Arp2/3 complex, confirmed the findings obtained with this pharmacological agent (CK-666) . Recently, Hetrick et al. (2013) provided new insight into determining the mechanism of CK-666 and its analog CK-869. Their data indicated that CK-666 can stabilize the inactive state of the Arp2/3 complex, blocking movement of the Arp2 and Arp3 subunits into the activated filament-like conformation, while CK-869 binds to a serendipitous pocket on Arp3 and allosterically destabilizes the short pitch Arp3-Arp2 interface.
The goal of the current study was to characterize the regulation of cell migration and to determine the mechanisms that can regulate cell movement through the actin cytoskeleton remodeling in the kidney cortical collecting duct principal cells. Particularly, we set out to investigate the role of Arp2/ 3-mediated changes in the actin cytoskeleton. Additionally, we investigated potential side-effects of CK-666 and its active and inactive analogs, which have been recently discovered and not intensively characterized. As seen in our studies, (1) inhibition of the Arp2/3 complex with CK-666 rearranged the actin filaments and decreased cell motility rate and (2) we show that this compound represents a useful tool for investigation of the Arp2/3 complex.
Materials and methods

Cell culture and chemicals
The M-1 mouse kidney principal cell line (Naray-Fejes-Toth et al. 2004 ) was obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA) and maintained with standard culture conditions (DMEM, 5 % FBS, 1× penicillinstreptomycin, 37°C, 5 % CO2); cells were reseeded upon confluence every 2 or 3 days. All reagents and media were purchased from Fisher Scientific (Waltham, MA, USA) or Biolot (St. Petersburg, Russia), unless noted otherwise. The inhibitor of the Arp2/3 complex CK-0944666 (CK-666) was purchased at Chemdiv (San Diego, CA, USA); CK-689 and CK-896 were purchased from EMD Biosciences (Merck, Whitehouse Station, USA).
Visualization of F-actin with rhodamine-phalloidin staining and image processing Cells were seeded onto 12-mm-round coverslips 24 h before experiments. Before staining, the cells were washed with PBS and fixed with 3.7 % paraformaldehyde. The cells were then treated with 0.1 % Triton X-100 for 5 min, washed with PBS and incubated with 2 μM rhodamine-phalloidin (SigmaAldrich, St. Louis, MO, USA) for 15 min at 37°C. Stained cells were mounted on glass slides covered with Vectashield mounting medium (Vector Laboratories, Burlingame, CA, USA). After staining, cells were visualized with a Leica TCS SP5 microscope (Leica Microsystems, Wetzlar, Germany) using a ×100 oil objective. The signal was excited at 543 nm and the emission was measured at 590 nm. Fluorescent images were processed with Leica Application Suite (LAS) software (Leica Microsystems) and open-source software ImageJ (National Institutes of Health, USA, http:// imagej.nih.gov/ij/) as described previously (Karpushev et al. 2010) .
Immunocytochemistry
Immunocytochemistry was performed on M-1 cell monolayers. M-1 cells were fixed with 4 % paraformaldehyde in PBS. Before antibody incubation, fixed cells were permeabilized with 0.1 % Triton X-100 in PBS and then blocked with 10 % donkey serum (1 h at 24°C). The cells were then incubated with the primary rabbit antibodies at 4°C overnight (anti-cortactin H-191, 1:100 (Santa Cruz Biotech), anti-β-catenin 1:100 (Abcam, ab2982), then incubated with Alexa 488-labeled secondary donkey anti-rabbit antibodies (1:300, 40 min at 37°C) and finally incubated with DAPI (0.05 μg/ ml) to stain the nuclei. Cells were mounted with Vectashield Mounting Medium (Vector Laboratories) and imaged with a confocal microscope (Leica TCS SP5; Leica Microsystems).
Cytotoxicity assay
For the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cytotoxicity assay, M-1 cells were seeded onto 12-well cluster plates and allowed to grow for at least 1 week to form a monolayer. Full conditioned media with FBS and antibiotics were changed to DMEM media without supplements 1 h before the experiment. Amounts of 100 or 200 μM of CK-666 or vehicle were added to the media and the cells were incubated for another 2 h. After treatment, MTT (Sigma-Aldrich) was added to the media (0.5 mg/mL) and cells were incubated for 4 additional hours. The medium was aspirated and replaced with isopropanol to solubilize the formazan products followed by optical density readings at 570 nm. The cell viability as a percentage of viable cells was calculated from the absorbance values as described previously (Karpushev et al. 2011) . Eight replicate wells were recorded for each measurement.
Live cell microscopy For live cell microscopy, M-1 cells were seeded onto 15-mmround glass coverslips 24 h before the experiment, respectively. Coverslips with attached cells were washed with extracellular solution for 5 min before being mounted in a chamber (0.4 ml, RC-25F; Warner Inst.). For time-lapse studies, they were placed in a temperature-, humidity-and CO 2 -controlled chamber on the heating stage of a Zeiss Axio Observer Z1 with a ×63/1.40 Plan-Apochromat oil-immersion objective (Carl Zeiss MicroImaging, Jena, Germany). Micrographs were taken every 3 min for an observation period of 4 h with an AxiocamMRm monochrome digital camera.
Motility rate measurements
The motility rate of M-1 cells was determined by a change in the position of the cell center. The values of the cell center position were obtained using a "centroid" function from the standard measurements plugin of ImageJ software from timelapse images acquired every 3 min. The distance of movement of single cells in 3-min intervals was calculated as the length of the displacement vector. The motility rate of at least 8-10 cells was continuously determined on defined cells before (control) and after addition of the compounds to the solution.
To obtain the mean motility rate of the cells, the displacement vectors were averaged on 3 intervals of time: before addition of the compound (vehicle, 2 h) and after 1 and 2 h. The mean motility rates after treatment were normalized to mean values, calculated for control conditions (vehicle) in each experiment. The parameters of cell motility were calculated from tracks of cell motion for each experiment. The direction of cell motility was assessed from polar plots as described previously (Cantarella et al. 2009) or from the D/T ratio, which is the ratio of the shortest direct distance from the starting point of each recording to the end point (D), to the total distance traversed by the cell (T) (Gu et al. 1999 ).
Wound-healing assay
For the wound-healing assay, M-1 cells were cultured in the DMEM media with 10 % FBS and seeded on 4-well plates 24 h before the experiment at a density of 2.0×10 5 cells/ml and cultured overnight at 37°C with 5 % CO 2 . The "wound" was created with a sterile 300 μL pipette tip, then cells were rinsed with PBS and the cell medium was changed for a fresh one. For time-lapse studies, the plates were placed in a temperature-, humidity-and CO 2 -controlled chamber on the heating stage of a Zeiss Axio Observer Z1 with a ×10/1.40 Plan-Apochromat objective (Carl Zeiss MicroImaging). Micrographs were taken every 1 h for an observation period of up to 24 h with an AxiocamMRm monochrome digital camera. Images were processed with ImageJ (National Institutes of Health, USA, http://imagej.nih.gov/ij/) and the wound size was calculated as a function of time.
Statistics
All data are reported as mean ± SEM. Data were compared using the Student's (2-tailed) t test; p<0.05 was considered significant.
Results
The effects of CK-0944666 on actin remodeling in M-1 epithelial cells
The Arp2/3 complex and its role in rearrangements of the actin cytoskeleton is very important in polarized monolayerforming cells. Several lines of evidence suggest that cytoskeletal elements control the apico-basal polarity of the proteins in epithelial cells, which is critical for the physiological function of these types of cells (Bryant and Mostov 2008; Wilson 2011) . Thus, our experiments were performed on polarized epithelial monolayers of the M-1 cells. As was described by Nolen and colleagues, the IC 50 values for CK-666 were 5 and 17 μM after 60 min of treatment as shown for Schizosaccharomyces pombe and Bos Taurus Arp2/3 complexes, respectively (Nolen et al. 2009 ). In our experiments on living cells, we initially started with CK-666 concentrations of 10 and 50 μM. However, we did not observe any significant differences in cytoskeleton dynamics when the cells were incubated with the drug for up to 1 h (data not shown); thus, in our experiments we tested higher concentrations of 100 and 200 μM. The cells were seeded on glass coverslips 1 day before the experiment, grown up to 80 % confluency and then incubated with CK-666 diluted in the DMEM media without serum and antibiotics in concentrations of 100 μM for 1 or 2 h and 200 μM for 2 h; corresponding control cells were kept in the DMEM media with the vehicle. Actin microfilaments were stained with rhodamine-phalloidin followed by confocal microscopy analysis.
To confirm that the observed rearrangements of the cytoskeleton caused by the treatment with CK-666 did not result from the side effects of the compound structure and are directly related to the Arp2/3 complex-targeted action of the drug, we tested both potent and inactive analogs of the CK-666. CK-869, a cell-permeable thiazolidinone compound was used as a positive control for CK-666. This compound was also shown to inactivate the Arp2/3 complex but exhibits different modes of binding compared to CK-666 (Nolen et al. 2009 ). As a negative control reagent we selected CK-689, a cell-permeable indolyl-methoxyacetamide, which has structural similarity with CK-666 but exhibits no Arp2/3 inhibitory activity (Nolen et al. 2009 ). Figure 1a -k illustrates representative staining of the actin filaments in control M-1 cells (Fig. 1a-b ) and cells treated with CK-666 (100 and 200 μM for 2 h, Fig. 1d , e and g, h, respectively). The figure shows the fluorescent images at ×100 (a, d, g, j) and close-up images at ×2.5 digital zoom (b, e, h, k). Inactive analog CK-689 was tested in M-1 cells at concentrations of 100 or 200 μM during 2 h of treatment. As shown by the rhodamine-phalloidin staining of M-1 cells in Fig. 1j , k, treatment with 200 μM CK-689 for 2 h did not affect the cytoskeleton structure (staining similar to control) (Fig. 1a, b) . A typical actin distribution pattern was observed that included intensive ruffling (shown by arrows). Cells treated with CK-666 showed highly concentrated and bundled actin stress fibers. This difference is particularly apparent in the line scans shown in the bottom row below the corresponding images (Fig. 1c, f, i, l) . These line scans show the fluorescence emissions (normalized to peak values at each time point) from the actin filaments in the areas defined by the white lines for the cells in the middle rows.
Inhibition of the Arp2/3 complex results in reduced lamellipodia formation Treatment of the cells with CK-666 significantly reduced the number of the cells with lamellipodia (Fig. 2a) indicating the major role of the Arp2/3 complex in the formation of these protrusions. Lamellipodia formation was up to 90 % decreased after exposure to CK-666 compared to the control cells and cells treated with CK689 as shown in Fig. 2a . Representative images of the rhodamine-phalloidin stained M-1 cells, which were used for the calculations of the lamellipodia number, are shown in Fig. 2b (control) and c (after treatment with 200 μM CK-666 for 2 h, lamellipodia are indicated with white arrowheads). Additionally, the cells were stained for the lamellipodia marker cortactin by using standard immunocytochemistry methods. Figure 2d , e show M-1 cells incubated with DMSO (d) or CK-666 for 2 h (e) and then stained for cortactin. As shown in this figure (the images were taken at the same focal plane), CK-666 significantly decreased the number of lamellipodia compared to control. Figure 3a -d illustrates an example of the M-1 cells' movement at different time points before and after treatment with 200 μM CK-666. The effects of CK-666 on the integrity of the M-1 cell monolayer were evaluated at these different time points. We found that treatment with CK-666 did not influence the cell-to-cell interactions and the monolayer remained intact for up to 2 h of exposure to the drug (Fig. 3e and closeup image f). This was confirmed with the immunofluorescence staining with anti-β-catenin antibodies to visualize the cell-to-cell contacts. As shown in Fig. 3g , h, the staining pattern of the M-1 cells treated with 200 μM CK-666 for 2 h (h) remains similar to the staining of the control cells (g, incubated with corresponding amount of the solvent-DMSO) demonstrating that cell-to-cell contacts are still intact. Control experiments (immunofluorescence staining without primary antibodies) did not reveal any staining (data not shown).
CK-666 neither affects monolayer integrity nor is it cytotoxic
To exclude the possibility that the effects of CK-666 on M-1 cells were mediated by a cytotoxic effect, we analyzed the effects of CK-666 on the morphology and viability of these cells. An MTT cytotoxicity assay was perfomed to assess any potential cytotoxic effect of CK-666. Supplementary Fig. S1 summarizes the viability of the M-1 cells treated with CK-666. Cytotoxicity was not detected when M-1 cells were either treated with 100 or 200 μM of CK-666 for 2 h.
Treatment with CK-666 significantly reduces M-1 motility rate
To determine whether CK-666, CK-869, or its inactive analog CK-689, affected cell motility, M-1 cells were seeded onto glass coverslips and grown to 60 % confluence 1 day before the experiments were performed. The cells were first treated with 200 μM of CK-666 and CK-689 for 2 h. For assessment of cell motility, a series of time-lapse images were acquired every 3 min over 4 h and subsequently analyzed. Figure 4 shows cell motility A representative image taken after treatment with CK-666 for 2 h at ×63 (e) and a close-up image at ×100 (f). g, h Immunofluorescent staining of M-1 cells with anti-β-catenin antibodies before (control, g) and after incubation with CK-666 for 2 h (h). Scale bar 25 μm from cells treated with vehicle, CK-666 and CK-689. As demonstrated in the representative images, CK-666 significantly reduced the distance travelled by the cells, whereas the vehicle and inactive CK-689 did not affect these parameters. Figure 5 shows the changes in cell motility rate after treatment with 200 μM CK-666 and CK-689. Motility rate was significantly reduced after inhibition of the Arp2/3 complex with CK-666 compared to the limited effects of CK-689. Similarly, treatment of M-1 cells with CK-869 (200 μM) over 2 h resulted in substantial rearrangements of the actin cytoskeleton structure ( Supplementary Fig. S2) ; the F-actin distribution pattern was changed similarly to that of the cells treated with CK-666 (Fig. 1) . The F-actin organization pattern after treatment produced highly bundled actin stress fibers. Motility rate was also significantly lowered compared to vehicle.
The direction of cell motility was also assessed from the D/T ratio, which was calculated in order to assess the parameters of cell motility after treatment with CK666 and CK-689. D is defined as the shortest distance between the starting and ending points of the cell motion track and T is the sum of all distances travelled by cells during the whole interval of observation. D/T ratios were not changed after treatment with CK666 or the negative control CK689, demonstrating the random nature of cell movement (Fig. S3a) . The polar plots supported the observation of random, non-directional cell motion as the graphs are almost round-shaped (Fig. S3b) . Thus, the treatment of cells with CK-666 and CK-689 had no effect on the D/T ratio or polar plot distribution indicating that CK and its analogs did not change the motility parameters. Therefore, we can conclude that CK-666 does not affect the directionality of cell movement nor does it affect monolayer integrity.
Wound-healing assay was performed in order to assess the motility of the M-1 cells in the presence of . Figure 6a -f shows 3 images from different time points of the representative wound-healing assay (first image, then 7 h and 14 h after the beginning of the experiment) of the untreated cell monolayer (a-c) and after treatment with 200 μM CK-666 (d-f). Averaged wound size (normalized to the starting point) as a function of time is shown on Fig. 6g . As is clear from the graph, the wound in control heals significantly more effectively than during the treatment of CK-666. Representative videos corresponding to the images shown in Fig. 6a -f can be found in supplementary material (Video S1A and Video S1B correspond to control and CK-666 treated wounds, respectively).
Discussion
In this research, we tested novel inhibitors of the Arp2/3 complex, CK-666 and its analogs, on cell motility and cytoskeleton organization in the immortalized mouse cortical collecting duct cell line, M-1. As seen from our data and from previously published data , CK-666 caused cytoskeleton rearrangements that were associated with the inhibition of the Arp2/3 complex. Sun et al. 2011 utilized 0.5 mM CK-666 for up to 12 h to study the expression and functions of the Arp2/3 complex during mouse oocyte meiotic maturation. This group reported that this concentration resulted in various effects including failure of the oocyte to asymmetrically divide, failure of the spindle to migrate and failure of the oocyte to form properly and undergo cytokinesis. We did not test such high concentrations in our experiments. We propose that the concentrations and the duration time of our study (100-200 μM; 1-2 h) are sufficient to inhibit the Arp2/3 complex in mammalian cells, yet not high enough to cause any side effects or affect cell viability. Thus, CK-666 and its analogs represent a powerful approach for studying both the Arp2/3 complex and the actin cytoskeleton in living cells.
Here, we observed that treatment of M-1 cells with CK-666 lowered the motility rate and reduced the number of the observed lamellipodia formation up to 90 %. These results are consistent with the observation that depletion of Arp2 and Arp3 with shRNA leads to the formation of filopodia and linear actin-based protrusions (Nicholson-Dykstra and Higgs 2008). Our observation that inhibition of the Arp2/3 complex destroys cell motility is consistent with the growing evidence that this complex is an important participant in cell migration processes. It has also been shown to be involved in the migration of fibroblast monolayers during wound healing (Magdalena et al. 2003; Warren et al. 2002) . Moreover, the Arp2/3 complex was found in cellular regions characterized by dynamic actin filament activity such as lamellipodia and motile actin patches in yeast (Warren et al. 2002) . Transverse arcs, which are stress fibers not directly anchored to substrate, are generated by endwise annealing of myosin bundles and Arp2/3-nucleated actin bundles at the lamella (Hotulainen and Lappalainen 2006) . The Arp2/3 complex has been shown to play a critical role in cancer. The invasion of cancer cells into the surrounding tissue is an initial step in metastasis, which is the leading cause of death from cancer. When cancer cells gain the ability to move, they break away from the primary tumor and colonize elsewhere in the body. Therefore, cancer cells generate cellular protrusions at the front of cells to facilitate the movement process. The driving force for membrane protrusion is localized polymerization of the actin filaments (Yamaguchi and Condeelis 2007) during which various membrane structures such as lamellipodia and invadopodia are formed. This process requires activation of the Arp2/3 complex to nucleate the formation of new actin filaments that exert a protrusive force on the membrane. Preventing metastasis, the spread of cancer cells from a primary tumor to a secondary site, might be an important therapeutic approach to cancer treatment. For example, renal collecting duct carcinoma arises from the epithelium of the collecting duct tubules within the renal medulla, which then secondarily invades the renal cortex (Carter et al. 1992; Zagoria et al. 1990) . A number of groups have examined the role of the Arp2/3 complex in lamellipodia assembly and cell motility using genetic and molecular approaches, such as siRNA and shRNA targeted against Arp2/3 complex subunits (Gomez et al. 2007; Steffen et al. 2006; Di Nardo et al. 2005 ) and the use of the mutants of Arp2/3 interacting proteins (Gupton et al. 2005; Shao et al. 2006; Strasser et al. 2004) . Results of these studies were interpreted by the authors in different ways. For instance, some authors demonstrated that loss of Arp2/3 complex components has little or no effect on general cell morphology, motility, or viability (Di Nardo et al. 2005) . Di Nardo et al. showed that knocking down expression of subunits of the Arp2/3 complex by 90 % had little impact on lamellipodia and therefore the Arp2/3 complex is not required for lamellipodia formation. However, 10 % of the Arp2/ 3 complex would still be around in the cells and such a knockdown experiment cannot be interpreted unequivocally, although the data are sound. Our results show a significant decrease in M-1 cells motility after inhibition of the Arp2/3 complex, which is in accordance with Suraneni et al. (2012) and Wu et al. (2012) .
The Bellini duct carcinoma (BDC), which is a rare and aggressive primary renal neoplasm, forms in the principal cells lining the distal collecting duct epithelium (Verdorfer et al. 1998 ) and distal renal tubules (Auguet et al. 2000; Dobronski et al. 1999) . Despite the fact that the collecting duct BDC comprises 1 % of all diagnosed duct renal cell cancer, about 50 % of patients with localized disease progress with distant metastasis. Currently, there is no effective therapy for metastatic collecting duct carcinoma and surgical removal of these metastases are often associated with a poor prognosis. Thus, CK-666 and its analogs might be promising pharmacological tools for future development of the approaches allowing targeted or local drug delivery, for instance, by an intratumoral injection approach at the early stages of cancer progression.
To summarize, we have found that the use of direct and non-toxic inhibitors of the Arp2/3 complex may be a beneficial treatment option for various metastatic cancers, which rely on tumor cell motility and invasion that are regulated by dynamics of the cortical actin cytoskeleton. CK-666 and CK-869 studied in this research showed high potency to inhibit the Arp2/3 complex, which decreased cell motility rate and inhibited formation of the lamellipodia. The ability to inhibit the formation of the Arp2/3 complex and effect lamellipodia formation not only provides insight into the mechanisms regulating cell migration in the kidney but it also provides rationale for investigating these mechanisms in cancer metastases in other organ systems.
